AVLN · Avalyn Pharma Inc.

The thesis

Avalyn Pharma's inhaled-antifibrotic case has cleared its first supply test without a break lower, and the Phase 2b MIST trial, guided to the second half of 2027, settles the clinical case. The shares closed at $25.74 on 28 October 2026, two sessions after the 180-day lock-up on pre-IPO holders ended on 26 October 2026.

The close was $24.64 on 15 October 2026, so the shares have risen 4.5% since the prior note. The three-month price change was -10.6% on 28 October 2026, and the 14-day relative strength index (RSI), a momentum gauge, was 50.1. The IPO price was $18.00.

The narrative is maturing: Raymond James initiated coverage on 2 October 2026 with an Outperform rating and a $60 target, and no company disclosure has followed in the Q3 pre-report window. Post-expiry reporting on insider sales was not found. Form 144 notices and block trades over the next two weeks would show whether holders are selling. The third-quarter report, expected about 11 November 2026, is the next dated test of spending and funding.

Bullish and bearish views on Avalyn Pharma Inc.

The bull case on Avalyn Pharma Inc. (AVLN), in brief: Enrollment finished above target. The bear case: Unlocked supply remains.

Bull case

• Enrollment finished above target. MIST randomized 398 patients against a target of 375, per the 12 August 2026 release. The primary endpoint is change in forced vital capacity (FVC), a measure of lung function.
• Analyst targets sit far above the price. Raymond James's $60 target (2 October 2026) and Morgan Stanley's $57 target (13 August 2026) compare with the $25.74 close on 28 October 2026.
• The shares held after the unlock. The close rose from $24.64 on 15 October 2026 to $25.74 on 28 October 2026, with the lock-up expiry in between.

Bear case

• Unlocked supply remains. The lock-up covered directors, executive officers and holders of substantially all stock and options, per the S-1/A filings. StockAnalysis lists about 25.15 million shares unlocking, and any Form 144 filing or follow-on offering would add supply.
• No efficacy datapoint for about a year. MIST topline is guided to the second half of 2027 and AURA (AP02) to late 2027, so price moves before then rest on flows and sell-side commentary.
• Spending is rising before validation. Research and development expense was $24.7 million in the second quarter, and the loss was $0.65 per share against a $0.53 loss estimate (Benzinga, 12 August 2026).
• The shares are well below their September levels. The adjusted close was $37.39 on 4 September 2026 and $25.74 on 28 October 2026, a gap no company disclosure has explained.

Price setup

The adjusted daily close was $25.74 on 28 October 2026. Investing.com reported a 52-week low of $24.15 on 2 October 2026, so the shares sit about 6.6% above the lowest level of their listing history as of that report. The $18.00 IPO price is the next reference below it.

The RSI rose from 33.9 on 15 October 2026 to 50.1 on 28 October 2026, which places momentum in a neutral range after the October decline. The shares have been above $24.15 on every adjusted close cited in this note.

Crowding evidence is limited to supply and timing. The third-quarter report is expected about 11 November 2026, the company has not confirmed the date, and Schedule 13D filings show large pre-IPO holders. Six firms rate the shares Moderate Buy with an average 12-month target of $60 (MarketBeat, 1 October 2026).

Catalysts, next 30 days

• ~11 November 2026, est.: Q3 2026 results. Earnings-tracking sites list this date with a consensus loss of $0.64 per share. The report tests the "into 2029" funding language against the $24.7 million quarterly R&D rate.
• ~30 September 2027, est.: MIST Phase 2b topline. Company guidance is the second half of 2027. This is outside the 30-day window but decides the clinical case.

Elapsed catalysts

• 29 October 2026 to mid-November: post-lock-up filings. Form 144 notices, Form 4 filings, block trades or a registered follow-on would show whether pre-IPO holders sell. (passed 8d ago)

What would change the view

The case breaks if MIST misses its primary FVC endpoint or shows a benefit no larger than oral antifibrotics deliver. A funding runway moved off "into 2029", or a follow-on offering priced below the current range, would weaken it before then. A daily close below $24, under the $24.15 52-week low, would break the post-listing range.

The case strengthens if third-quarter R&D stays near $24.7 million, runway language holds, and unlocked holders sell little through mid-November.

What it trades with

AVLN trades on its own trial timeline and the supply of unlocked shares. It has no product revenue. Small-cap biotech sentiment and recent IPO lock-up expiries move the shares more than any sales line. No current theme cluster carries the name.